RxDoctor Payments Data

Wayne Scott, MD

Ophthalmology · Brooklyn, NYNPI 1942274980

Payments from drug & device makers

$7,093in general payments, 2019–2025

Across 154 payments — averaging $46.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$4K
  • AbbVie$1K
  • Alcon$686
  • Genentech USA, Inc.$250
  • Regeneron Healthcare Solutions, Inc.$216
  • Amgen$175
  • plus $900 from 16 others

What the payments were for

  • Food & beverage$7,05399%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,093 in reported general payments places this provider in the 80th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$103,514
Medicare patients
289
Services billed
1,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine103$71,915
Brimonidine Tartrate941$66,578
LumiganBimatoprost151$63,634
CombiganBrimonidine Tartrate/Timolol105$36,331
RhopressaNetarsudil Mesylate76$29,784
SimbrinzaBrinzolamide/Brimonidine Tart99$21,116
Prednisolone Acetate489$20,893
Timolol Maleate1,149$20,846
Latanoprost2,969$20,324
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol65$14,053
Alphagan PBrimonidine Tartrate33$10,126
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat664$9,916
Brinzolamide51$8,926
RocklatanNetarsudil Mesylat/Latanoprost25$8,330
Acetazolamide101$6,667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$1,216$182,007392 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$143$38,114101 claims
AlconSimbrinza$686$21,11699 claims
Bausch & Lomb Americas Inc.Vyzulta$123$4,62611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →